display
A trial against a molecular biologist at the Hamburg Regional Court began on Wednesday for the manufacture and sale of an unapproved cancer drug.
The public prosecutor accused the 72-year-old of having sold the drug GcMAF to doctors and alternative practitioners in Germany, Austria, Switzerland and other countries from January 2014 to May 2017.
The accused was neither licensed as a doctor or pharmacist, nor did he have a license to manufacture the agent in his laboratory (Ref .: 624 KLs 8/19).
The customers each had to fill out a form in which they truthfully stated that they had manufactured the drug themselves.
In this way the Medicines Act should be circumvented.
The public prosecutor's office assumes 400 deliveries, through which the defendant raised over 1.9 million euros.
Most of the time, the company from Hamburg-Bahrenfeld is said to have sent orders for ten ampoules at a price of a good 3400 euros.
As the prosecutor's listing showed, there were apparently a number of regular customers.
display
The drug GcMAF may be manufactured and administered individually for patients by doctors and alternative practitioners, said a court spokesman.
It is used for immunotherapy, which is why it is difficult to prove its effectiveness.
A license is required in any case for the production of the agent for intravenous administration.
A business partner of the defendant informed the authorities in 2016.
For the unauthorized placing of finished medicinal products on the market, the defendant faces up to one year imprisonment per case if convicted.
Trading in prescription drugs without permission can result in a fine or up to three years in prison.
Some of the indicted cases are threatened with statute of limitations.
That is why negotiations will be held against the 72-year-old under corona conditions, said the spokesman.
The criminal chamber has set four more dates until March 26th.